The Micro Float That Fueled a +413% Squeeze: How VRAX's Filings Revealed What Was About To Come (Forensic Filing Analysis)

TLDR

• VRAX surged +413% for the full move ($2.57 on July 1 to $13.19 on July 9) and +112% close-to-close this week ($2.95 to $6.27 across the four sessions July 6-9) after a $3.3M preferred-investment-option exercise and a multi-country commercial supply agreement with Fosun Diagnostics landed on the same day. The tradeable float is just 780,000 shares following a 1-for-25 consolidation.
• Market cap sits at $2.5M with $4.8M current cash and 12.7 months of runway against a quarterly burn of -$1.14M — this is a micro-cap balance sheet, not a distressed one.
• The primer filings were all 6-Ks: the 1-for-25 Share Consolidation announced June 24 (6-K) compressed the float, and the July 9 6-K confirmed the option exercise and Fosun deal that ignited the tape.
• On July 9, VRAX traded 71,958,787 shares — roughly 92x the 780K float. Short interest was only 5.5%, so this was a micro-float rotation squeeze, not a classic high-short-interest unwind.
• A $10,000 position tracking the full move returned $51,320 (+413%); the cleaner close-to-close swing captured $11,250 (+112.5%).

The Setup: A Micro-Float Foreign Issuer After a 1-for-25 Consolidation

VRAX is a UK-domiciled Nasdaq-listed biotech (Virax Biolabs Group Limited) that reports as a foreign private issuer, which means it files 6-K current reports and an annual 20-F rather than the 8-K/10-K/S-3/424B5 stack a domestic small-cap uses. That distinction matters for anyone screening filings: the entire VRAX dilution and catalyst chain lives in a different form set, and a trader watching only for 424B5 pricing supplements would have missed every signal here.

The structural spark was mechanical. On June 24, VRAX announced a 1-for-25 Share Consolidation (reported via 6-K). That reverse split collapsed the tradeable float to 780,000 shares and left the market cap at $2.5M. A sub-1M-share float is the powder keg — it takes almost no incremental buying to rotate the entire float, and once a real catalyst hits, the order book cannot absorb it. Short interest was a modest 5.5% and institutional ownership just 4.6%, so the fuel here was float scarcity, not a crowded short. This is the same float-rotation mechanic covered in Float Rotation Explained: When Volume Exceeds the Float — when a day's volume runs many multiples of the float, price discovery breaks in favor of the buyers.

Filing Timeline: What the 6-Ks Revealed Before the Run

The forensic read is that VRAX telegraphed the setup across a tight sequence of 6-K filings, and the June 24 consolidation was the turn. Over the last 90 days the filing record shows 8 total filings: one 20-F (July 3), six 6-K filings (July 9, June 24, June 12, May 26, May 22, April 14), and one SCHEDULE 13G/A (May 15). There were zero S-3, S-1, or 424B5 registration filings from VRAX in the window — the whole story is 6-K driven.

The two July 9 headlines are the payload: "Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds" and "Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics." A cash infusion and a revenue-bearing commercial agreement, dropped on the same session into a 780K float, is the exact combination that produces a vertical move. The June 24 consolidation set the stage two weeks in advance; the July 9 6-K lit it.

Share Structure Impact: The 780K Float and the Facility Overhang

The active dilution overhang on VRAX is small and mostly out of the money, which is why the squeeze had room to run. The dossier splits nine facilities into five active and four completed/historical. Only the active facilities are current dilution risk.

Active (currently exercisable or drawable):

Two details define the risk. First, the December 2023 Shelf carries $22,078,848 remaining in capacity but sits under a baby-shelf restriction — the price must exceed $95.49 for the company to draw the primary shelf. At July prices the shelf is effectively frozen, so the largest facility on the books was not a live threat during the run. Second, the October 2023 Warrants strike at $73.35 — deep out of the money and irrelevant to price action in the $2-$13 zone.

The only facility near the action is the December 2025 Warrant at a $10.00 strike (500,000 warrants). VRAX traded through $10 intraday on July 9 on its way to the $13.19 print, which puts that tranche in the money for the first time. The two HC Wainwright ATMs are tiny — $737,301 and $675,693 remaining — meaning combined ATM dry powder under $1.5M against a session that turned over 72M shares.

The four completed/historical facilities — the November 2022 PIPE Warrants, November 2022 PIPE Pre-Funded Warrants, March 2023 Series B Investment Options, and March 2023 Series A Investment Options — are already-raised capital. They are not active overhang and do not factor into current dilution risk. The July 9 "Preferred Investment Options" exercise for $3.3M is the live event: options getting exercised puts cash in the company and shares into circulation, and the market read it as validation rather than dilution given the accompanying Fosun commercial deal.

Price Action: From $2.57 to $13.19

The move built over four sessions and then went vertical on July 9. Before the run, VRAX chopped in the low $3s post-consolidation — $3.30 on June 29, $2.94 on June 30, $2.74 on July 1 — on trivial volume. The expansion began July 2.

The July 9 session tells the whole story of a micro-float catalyst day. Pre-market ran from a $3.04 open to an $11.05 close as the 6-K catalysts hit the wire. The regular session opened at $11.09, printed the HOD of $13.19, and then faded to a $6.27 regular-session close — a -43.5% regular-session candle off a gap that was still up massively from the prior $3.23 close. After hours drifted from $6.38 to $5.55. Volume of 71,958,787 against a 780,000 float is a ~92x float rotation in a single day. The full move — $2.57 on July 1 to $13.19 on July 9 (+413%) — is verified; the four-day close-to-close move was +112% ($2.95 to $6.27).

The tell for anyone reading the tape live: an eight-figure share count on a stock with a 780K float is not orderly accumulation. It is the entire float changing hands multiple times per hour — mechanical price discovery on a supply constraint.

That -43.5% regular-session fade is also the honest half of this trade. A trader who bought the $11.09 regular open and held to the $6.27 close lost -43.5% on the day — while the full-day MFE from the $2.57 base to the $13.19 HOD offered +413%. Same ticker, same date, opposite outcomes depending entirely on entry and exit. This is the exact dynamic broken down in MFE vs Close Price: How a -36% Red Day Offered +1,075% Profit Potential.

The Opportunity and the Risk

The opportunity in a VRAX-style setup is the pre-catalyst compression on a freshly consolidated micro-float; the risk is the active-facility overhang and the extended-hours volatility. Both are quantifiable here.

On the opportunity side: the June 24 consolidation compressed the float to 780K two weeks before the catalyst, and the July 2 expansion candle (+14.8% on 228,744 shares) flagged that something was building while price was still in the low $3s. A $10,000 position tracking the full move returned $51,320 (+413%). The more realistic close-to-close swing on the four-day run captured $11,250 (+112.5%). Even the July 2 expansion-to-July 9 window was tradeable in daylight without needing to nail the exact HOD.

On the risk side: the active overhang is limited but not zero. The $10.00-strike December 2025 warrants (500,000) went in the money on July 9, which introduces supply from warrant holders exercising and selling. The two HC Wainwright ATMs together hold under $1.5M of remaining capacity — small relative to the day's turnover but a lever the company can pull into strength. With $4.8M cash and 12.7 months of runway, VRAX is not in a forced-financing corner, so there was no distressed-raise gun to the head during the run. The larger risk was purely mechanical: a -43.5% regular-session fade off the open, and a pre-market range from $3.04 to $11.05 that is two-way violence, not a trend. For the mechanics of why micro-floats squeeze and unwind this fast, see Short Squeeze Mechanics: The Float Rotation Behind FCUV's +239.4% MFE.

For market-wide context on where these facilities sit: across the active universe there are approximately ~5,700 active warrant facilities, ~3,000 shelves, ~2,000 ATM programs, and ~1,400 convertible-note facilities (approximate counts; exact totals withheld). VRAX's own overhang — two sub-$1M ATMs, a frozen baby shelf, and mostly out-of-the-money warrants — is light by that standard, which is part of why the float could run so cleanly.

How VRAX Fits This Week's Tape

VRAX was one of six multi-day continuation runners this week, and it did it against a small-cap-friendly backdrop. The macro call is Small-Cap Leadership: the Russell 2000 (IWM) closed at $297.24, -1.8% from its 52-week high ($302.72), up +4.3% over 20 days and outpacing the S&P 500 (SPY) at $751.71 (-1.1% from its high) and the Nasdaq 100 (QQQ) at $723.28 (-3.4% from its high). When small caps lead, micro-float squeezes get more follow-through.

The week ran runner-heavy — 18 names up 50%+, 3 up 100%+ — against a four-week baseline of about 7 runners 50%+ per week. VRAX printed +132.2% ($2.70 → $6.27) on the weekly split-adjusted board, third behind CLRO (+170.8%) and LHSW (+145.1%). Healthcare put two names on the top-10 list (VRAX and ZCMD +94.3%). The other multi-day continuation candidates on the same four-session window were TVRD (+95.6%), FBRX (+76.9%), TDTH (+74.3%), WRAP (+59.1%), and CLRO (+51.4%). For the sector-rotation read on that cohort, see CLRO +185% in 4 Days — Communications Equipment Leads the Small-Cap Rotation.

The filing-forensics playbook that caught VRAX is the same one that surfaced the +4,194% Reverse-Split Squeeze in INHD: a reverse split compresses the float, the filings telegraph it in advance, and a catalyst on the compressed float does the rest.

How to Find These Setups Before They Run

You catch a VRAX before it runs by screening for the reverse-split-plus-micro-float structure and then reading the filing chain on the SEC research tool. Here is the concrete workflow.

Start in the SNACS scanner. Set the Float filter under 1M shares to isolate freshly consolidated micro-floats, add a price band of $1-$15, and turn on the Dilution Alerts column so you can see active facilities at a glance. Sort by RVOL descending to surface the names where volume is already expanding against a thin float — VRAX's July 2 expansion candle (+14.8%) would have flagged well before the July 9 vertical. Save that filter as a named preset so it re-runs live every session.

When a name surfaces, click the ticker to open the ticker details page. That gives you the chart, the dilution-risk panel showing active shelf/ATM/warrant facilities, recent news, and the SEC filings inline — you can confirm the 1-for-25 consolidation and the sub-1M float without leaving the scanner. Then move to the SEC research tool: the Dilution Snapshot shows active facility counts, shares at risk, and the lowest exercise price, and the Filing Browser lets you read the 6-K chain directly — for a foreign issuer like VRAX, that is where the consolidation and the option-exercise catalysts live, not in the 424B5 stream. In the same three-day window, the broader market saw 7 total 424B5 pricing supplements from 4 tickers and 3 fresh S-3 shelf registrations from 3 tickers — domestic dilution signals — but VRAX's signals were entirely in its 6-K flow.

Finally, wire it to alerting. Build a setup in the AI Playbook Builder — historical context (post-consolidation micro-float base) → trigger (RVOL and volume expansion) → entry → exit — and let live matching monitor the scanner. When a ticker matches, a star indicator appears in the stream, and you get in-app, email, or SMS alerts. Link the saved scan to a Dynamic Watchlist so qualifying tickers auto-populate in real time. That combination — micro-float screen, filing confirmation on the ticker details page, and playbook live matching — is how you get positioned before the catalyst 6-K hits, not after the gap.

What to Watch Next

VRAX now trades with a $10.00-strike warrant tranche in the money and two small ATMs the company can tap into strength — so the next 6-K is the one to read closely for any capital-markets activity. On the tape, the four-day continuation cohort (VRAX, TVRD, FBRX, TDTH, WRAP, CLRO) is the continuation watchlist into next week; runner-heavy weeks under Small-Cap Leadership tend to hand off, and the week-arc data shows sustained runner-heavy tapes as the most common pattern over the last five weeks. Keep the micro-float scanner preset live, and let the filings tell you which consolidated shell is coiling next.

FAQ

What caused the VRAX stock squeeze in July 2026?

VRAX squeezed because a 1-for-25 share consolidation on June 24 compressed the float to 780,000 shares, and then two catalysts hit on July 9 — a $3.3M preferred-investment-option exercise and a multi-country commercial supply agreement with Fosun Diagnostics. On a 780K float, that combination drove 71,958,787 shares of volume (about 92x the float) and a full move of +413% from $2.57 to $13.19.

How do you check SEC filings for dilution on a foreign issuer like VRAX?

For a foreign private issuer, dilution and catalyst disclosures live in 6-K current reports and the annual 20-F, not the 8-K/S-3/424B5 forms domestic companies use. In the SNACS SEC research tool, open the Dilution Snapshot for active facility counts and the lowest exercise price, then use the Filing Browser to read the 6-K chain directly — for VRAX, the June 24 consolidation and the July 9 option-exercise catalyst both appeared as 6-K filings.

What is a baby shelf restriction and why did it matter for VRAX?

A baby shelf restriction limits a company with a small public float from drawing its primary shelf below a set price threshold. VRAX's December 2023 Shelf holds $22,078,848 in remaining capacity but requires the price to exceed $95.49 to draw it — so at July prices the largest facility on the books was effectively frozen and did not act as live dilution overhang during the run.

How much could a trader have made on the VRAX move?

A $10,000 position tracking the full move from $2.57 on July 1 to $13.19 on July 9 returned $51,320 (+413%). The cleaner four-day close-to-close swing from $2.95 to $6.27 captured $11,250 (+112.5%). A trader who instead bought the $11.09 regular-session open on July 9 and held into the $6.27 close lost -43.5% — the entry and exit mattered far more than the direction.

Why is a low float important for a squeeze?

A low float means very few shares are available to trade, so incremental buying pressure moves price violently because the order book cannot absorb it. VRAX's 780,000-share float after the 1-for-25 consolidation let a single session turn over the float roughly 92 times, which is mechanical price discovery on a supply constraint rather than orderly accumulation.

Was the VRAX move a short squeeze or a float rotation?

It was primarily a micro-float rotation, not a classic short squeeze. Short interest was only 5.5% and institutional ownership 4.6%, so there was no crowded short position to unwind — the driver was float scarcity meeting a same-day cash-and-commercial catalyst on a 780,000-share float.

How do I set up a scanner to find micro-float squeeze setups?

In the SNACS scanner, set the float filter under 1M shares, a price band of $1-$15, turn on the Dilution Alerts column, and sort by RVOL descending. Save it as a named preset, click any qualifying ticker to open the ticker details page for its filing chain and dilution panel, then wire the setup to the Playbook Builder for live star-indicator alerts.